Assessing the Real-World Safety of Tralokinumab for Atopic Dermatitis: Insights from a Comprehensive Analysis of FAERS Data

This study assessed the safety of tralokinumab for atopic dermatitis using FAERS data, analyzing 849 reports of adverse events. It confirmed known reactions like injection site reactions and conjunctivitis, and identified new potential risks such as dizziness, headache, nausea, vomiting, hair loss, and acne. Hair loss was particularly noted for its psychological impact, highlighting the need for proactive management. The study underscores the importance of monitoring adverse events, especially within the first month of treatment, to improve patient quality of life and treatment adherence. Limitations include potential data inaccuracies and a predominance of U.S.-sourced data, suggesting the need for further international and long-term research.